about
CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa BHVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen speciesIdentification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytesHomeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.Laparoscopic splenectomy: a personal series of 140 consecutive cases.Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomySafety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studySafety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicityRecurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells.Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma.The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies.The evolving role of alemtuzumab in management of patients with CLL.t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignanciesHHV-8-unrelated primary effusion-like lymphoma associated with clonal loss of inherited chromosomally-integrated human herpesvirus-6A from the telomere of chromosome 19q.Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment.Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.Activity of thalidomide and lenalidomide in mantle cell lymphoma.A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
P50
Q24290440-98CAEBAB-B4FD-4E9E-99AA-B80BFA27B7FCQ24632831-2B33293B-A84E-4E9D-A69E-196FEE270EA6Q24648598-F2B98092-A776-45DF-AEAE-A357AF200711Q27312570-FCAE0985-E2B2-4254-A736-3FC515BC50AAQ27851580-5AB38255-D3BE-49C5-BBBD-2D50FB36B3E5Q33389710-A24AAD69-E8BE-471B-B613-D173AF85C832Q33417186-8F41E434-BCC5-475A-B15E-7C6B36B94B32Q33438732-F52EBF21-FF51-4E27-9873-2E6ED19E66A1Q33574197-96F856A5-51F1-4A4F-ADBD-E05DF8D49968Q33896738-20B27DE4-F4A9-4EF2-B0D0-78041297CF76Q34112913-519D7FF0-5719-45E6-942C-2FCF2DF9C591Q34347222-6D2F23B0-A46F-4D01-ADAC-5E04DB070F34Q34752063-FD157F7F-3099-441F-8845-35F745D0B87AQ35037313-84144075-FB95-4D92-9BEF-A5B7C6FCCBA0Q35140188-B2C2475B-E8D7-4F88-9FC2-C4179E5AC295Q36292883-B93E5359-223D-4A48-8C48-C1959C9940D8Q36395591-69AF5E6C-11A7-4F56-B736-2F27C7BF247DQ36517276-69A1DC0A-6669-4E1A-92EF-6C9CD09A66D1Q36656811-8E8C2EDC-8EFD-49AF-9C9E-560539FE20D1Q36799831-FA4092A7-9E72-4D7A-9DC8-8BEEB9827541Q37170788-C481143A-A99A-4406-88DA-E24783912E1BQ37255665-001915E6-8577-4C9A-8262-6D2454377302Q37479342-0BD3D8E6-8BC5-4D98-94AE-1C1850F569D4Q37482750-D1D46E4F-17A6-43D5-9121-DC047767891EQ37641045-64351963-BCC3-47EB-9CB7-D1979031984AQ38167332-E38AE5B0-FB5C-49E7-9486-468A56DC4CD7Q38205852-C8FE4F2D-23B3-4625-81A9-2629DE861A72Q38755091-2D993B2E-57CD-4A26-8162-3CAC9FEE87C1Q38764010-70EBF25E-9B29-46C6-A43C-11086237B785Q39077324-60205C22-ED3C-4048-B3D7-6E61095290E6Q39093058-101F2FDE-43DD-47C2-8B7C-26EB715F7716Q39267135-552BC746-8989-4B76-8B6A-147D80B7C26DQ39311207-C6673B20-C7F8-4A1F-881B-97F61C91BC92Q39554347-FD9B2642-B3ED-40B5-8F77-4DCEBB8103C7Q39775939-DE42ED2A-E1AB-4741-9FA2-6BA3906977ACQ40007589-07F2B3E9-239A-4E05-857C-A5029F8124DEQ40070558-27FBD993-0E02-4717-8843-5E803C26CD85Q40127987-D53B26ED-F454-4299-89A9-DF86BA588F61Q40389351-C6D537E9-EC21-468F-951E-15D12756897AQ40391965-F0EAEAA1-1E47-4D5E-8703-C61279C03A65
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin Dyer
@ast
Martin Dyer
@en
Martin Dyer
@es
Martin Dyer
@nl
Martin Dyer
@sl
type
label
Martin Dyer
@ast
Martin Dyer
@en
Martin Dyer
@es
Martin Dyer
@nl
Martin Dyer
@sl
prefLabel
Martin Dyer
@ast
Martin Dyer
@en
Martin Dyer
@es
Martin Dyer
@nl
Martin Dyer
@sl
P106
P1153
7201700604
P31
P496
0000-0002-5033-2236